For example, under the Accelerating Medicines Partnership, the NIH and ten biopharmaceutical companies will fund a five-year effort to validate promising targets in three disease areas. Other initiatives include efforts in Alzheimer’s research to test competing drugs against one shared “placebo arm” in clinical trials, and in cancer research to test multiple therapies in a single trial and identify the most responsive patients.